Retrospective analysis of patients with advanced or metastatic gastric cancer in Colombia

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
   PubMed Web of Science ®Google Scholar
• Piazuelo MB, Correa P. Gastric cancer: overview. Colomb Med. 2013;44:192–201.
   PubMed Web of Science ®Google Scholar
• Torpy JM, Lynm C, Glass RM. JAMA patient page. Stomach cancer. JAMA. 2010;303:1771.
   PubMedGoogle Scholar
• Bang YJ, Yalcin S, Roth A, et al. Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics. Asia-Pac J Clin Oncol. 2014;10:38–52.
   PubMed Web of Science ®Google Scholar
• Daza DE. Cáncer Gástrico en Colombia entre 2000 y 2009 [Gastric Cancer in Colombia between 2000 and 2009]. 2012. Spanish.
   Google Scholar
• Restrepo AF, Riveros JH. Guías de Práctica Clínica-GPC Para el Cancer Gastrico [Practice guidelines for Gastric Cancer]. 2014. Spanish.
   Google Scholar
• Torres J, Correa P, Ferreccio C, et al. Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of Pacific Latin America. Cancer Causes Control. 2013;24:249–256.
   PubMed Web of Science ®Google Scholar
• Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of tumours of the digestive system. 4th ed. Lyon, France: International Agency for Research on Cancer; 2010.
   Google Scholar
• Lauren T. The two histologic main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
   PubMedGoogle Scholar
• Hu B, El Hajj N, Sittler S, et al. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251–261.
   PubMedGoogle Scholar
• Kim R, Tan A, Choi M, et al. Geographic differences in approach to advanced gastric cancer: is there a standard approach? Crit Rev Oncol Hematol. 2013;88:416–426.
   PubMed Web of Science ®Google Scholar
• Bauer K, Schroeder M, Porzsolt F, et al. Comparison of international guidelines on the accompanying therapy for advanced gastric cancer: reasons for the differences. J Gastric Cancer. 2015;15:10–18.
   PubMed Web of Science ®Google Scholar
• Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. WJG. 2016;22:2403–2414.
   PubMed Web of Science ®Google Scholar
• Janowitz T, Thuss-Patience P, Marshall A, et al. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer. 2016;114:381–387.
   PubMed Web of Science ®Google Scholar
• The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Gastric Cancer (version 2). 2016. [cited 2018 Dec 9]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
   Google Scholar
• Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38–v49.
   PubMed Web of Science ®Google Scholar
• Japanese Gastric Cancer Association. Japanese Gastric Cancer treatment guidelines 2014 (version 4). Gastric Cancer. 2017;20(1):1–19. doi:10.1007/s10120-016-0622-4.
   Google Scholar
• López-Moncayo H, Ospina-Nieto J, Rubiano-Vinueza J, et al. Cáncer Gástrico [Gastric Cancer]. Guías de Manejo en Cirugía [Surgical Management Guidelines]. Bogotá, Colombia: Asociación Colombiana de Cirugía; 2009. Spanish.
   Google Scholar
• Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. JCO. 2006;24:2903–2909.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–168.
   PubMed Web of Science ®Google Scholar
• Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study–FFCD 9803. JCO. 2004;22:4319–4328.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Saltz L, Twelves C, et al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol. 2011;22:2604–2609.
   PubMed Web of Science ®Google Scholar
• Aguado C, Garcia-Paredes B, Sotelo MJ, et al. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? WJG. 2014;20:6092–6101.
   PubMed Web of Science ®Google Scholar
• Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20:1529–1534.
   PubMed Web of Science ®Google Scholar
• Starling N, Rao S, Cunningham D, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. JCO. 2009;27:3786–3793.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26:141–148.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435–1442.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450–1457.
   PubMed Web of Science ®Google Scholar
• Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2010;21:71–77.
   PubMed Web of Science ®Google Scholar
• Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. JCO. 2014;32:3520–3526.
   PubMed Web of Science ®Google Scholar
• Shi J, Gao P, Song Y, et al. Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis. Sci Rep. 2017;7:5319.
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306–2314.
   PubMed Web of Science ®Google Scholar
• Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78–86.
   PubMed Web of Science ®Google Scholar
• Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. JCO. 2012;30:1513–1518.
   PubMed Web of Science ®Google Scholar
• Roy AC, Park SR, Cunningham D, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013;24:1567–1573.
   PubMed Web of Science ®Google Scholar
• Apicella M, Corso S, Giordano S. Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget. 2017;8:57654–57669.
   PubMedGoogle Scholar
• Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–221.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–4997.
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). JCO. 2003;21:54–59.
   PubMed Web of Science ®Google Scholar
• Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–1069.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Shimamura T, Hyodo I, et al. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer. 2006;94:1803–1808.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu YY, Li W, et al. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol. 2014;73:1155–1161.
   PubMed Web of Science ®Google Scholar
• Okabe H, Ueda S, Obama K, et al. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol. 2009;16:3227–3236.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Tanabe K, Taomoto J, et al. Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett. 2010;1:743–747.
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Cancerología [National Cancer Institute]. Bogotá, Colombia. [cited 2018 Jul 20]. Available from: http://www.cancer.gov.co/. Spanish
   Google Scholar
• Instituto de Cancerología S.A. [Cancer Institute]. Medellín, Colombia. [cited 2018 Jul 20]. Available from: https://institutodecancerologia.lasamericas.com.co/. Spanish.
   Google Scholar